Chaitan Mugili has been appointed General Manager at The Westin Riverwalk, San Antonio
The Westin Riverwalk, San Antonio is proud to welcome back Chaitan Mugili as its newly appointed General Manager - a significant full-circle moment in his distinguished hospitality career. Nearly two decades after serving as Front Desk/Housekeeping Manager at the same property, Mugili now returns to lead the hotel as its top executive.
Before rejoining The Westin Riverwalk, Mugili most recently served as General Manager for Winston Hospitality, where he led operations for the AC by Marriott & Element by Westin in downtown San Antonio. There, he managed 343 rooms, a rooftop bar, and multiple commercial tenants - overseeing a team of 150 associates across every operational discipline.
Over the course of his 20+ year career, Mugili has held executive leadership roles with Marriott, Hyatt, and Starwood Hotels, consistently improving guest satisfaction, financial performance, and team culture. He is a two-time General Manager of the Year recipient - recognized by Marriott Hotels (2018) and SAHLA (2021) - and led his previous properties to top performance rankings in guest experience. Chaitan's leadership extends beyond hotel walls. He currently serves as Chairman of the San Antonio Hotel & Lodging Association (SAHLA) and sits on the board of the San Antonio Visitor Alliance.
On May 29, 2025, Mugili was formally recognized by the Texas House of Representatives with a certificate of appreciation honoring his "commitment to excellence and service within our community and the State of Texas." He was also invited to the Texas State Capitol to be honored with a Gallery Recognition on the House Floor - a tribute to his impactful work advancing advocacy and education through SAHLA. His broader community contributions include raising over $16,000 for charitable organizations such as the Leukemia & Lymphoma Society and the Susan G. Komen Foundation, as well as volunteering with the San Antonio Food Bank. As he steps into this new chapter, Mugili brings not only operational expertise but a deep personal connection to the hotel, its culture, and its community. The Westin Riverwalk is poised to thrive under his vision and leadership.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Why Novo Nordisk Stock Sank by Nearly 4% Today
Novo Nordisk (NYSE: NVO) stock had a Monday to forget, as news from a top rival dampened sentiment on the Danish pharmaceutical company. A price target cut from an analyst tracking the company only exacerbated the situation. By market close that day, Novo Nordisk's shares were down by 3.5%, in contrast to the generally buoyant S&P 500 (SNPINDEX: ^GSPC), which edged almost 1% higher. A rival makes a move That rival is none other than giant U.S. pharmaceutical company Eli Lilly. It announced that it will make the highest dosages of its Zepbound weight-loss drug available to any adult with a qualifying prescription via its website beginning in August. Zepbound, a direct competitor to Novo Nordisk's pioneering Wegovy, is already available on Lilly's website, albeit in lower doses. With the addition of the two highest-dose versions, all dosages of the drug will be offered through the company's portal. With this, Eli Lilly has a fine chance of poaching more market share from the European company. Price target cut Meanwhile, well before the market open, J.P. Morgan prognosticator Richard Vosser cut his price target on the company. He now feels its Denmark-listed stock is worth 650 kroner ($101) these days, down significantly from his previous fair-value assessment of 1,000 kroner ($155). He maintained his overweight (i.e., buy) recommendation, however. Neither of these developments is positive for Novo Nordisk. However, investors didn't react by panic-selling the stock; instead, it suffered only a minor sell-off. This is telling; Wegovy is still a hotly popular drug and should remain so, given the high levels of obesity in this country, and Americans' desire for a relatively easy fix for this. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Yahoo
9 minutes ago
- Yahoo
Bank of America (BAC) Could Be a Great Choice
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases. Based in Charlotte, Bank of America (BAC) is in the Finance sector, and so far this year, shares have seen a price change of 0.32%. The nation's second-largest bank is paying out a dividend of $0.26 per share at the moment, with a dividend yield of 2.36% compared to the Financial - Investment Bank industry's yield of 1.18% and the S&P 500's yield of 1.57%. Taking a look at the company's dividend growth, its current annualized dividend of $1.04 is up 4% from last year. In the past five-year period, Bank of America has increased its dividend 4 times on a year-over-year basis for an average annual increase of 8.84%. Any future dividend growth will depend on both earnings growth and the company's payout ratio; a payout ratio is the proportion of a firm's annual earnings per share that it pays out as a dividend. Bank of America's current payout ratio is 31%. This means it paid out 31% of its trailing 12-month EPS as dividend. Earnings growth looks solid for BAC for this fiscal year. The Zacks Consensus Estimate for 2025 is $3.68 per share, which represents a year-over-year growth rate of 12.20%. Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. But, not every company offers a quarterly payout. For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, BAC is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Powys County Times
9 minutes ago
- Powys County Times
Doctor who helped give Matthew Perry ketamine will plead guilty to drug charges
A doctor charged with giving Matthew Perry ketamine in the months leading up to the Friends star's overdose has agreed to plead guilty, authorities said on Monday. Dr Salvador Plasencia has agreed to plead guilty to four counts of distribution of ketamine, federal prosecutors said in a statement. They said the plea carries a maximum sentence of 40 years in prison, and Plasencia is expected to enter the plea in the coming weeks. Plasencia and a woman accused of being a ketamine dealer had been the primary targets of the prosecution, after three other defendants, including another doctor, agreed to plead guilty in exchange for their co-operation. Plasencia had been scheduled to start trial in August.
